Personalised to support your treatment decisions

Find disease awareness content and supporting materials, including relevant drugs

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Learning Zones

8 year old child with redness and peeling of the skin on the body.

Overview

Atopic Dermatitis in Paediatric Patients

1 mins

Unrecognizable female doctor holding graphic virtual visualization model of Lungs organ in hands. Multiple medical icons on the background.

Learning Zone

Type 2 Inflammation in COPD

1 mins

Learning Zone

Advances in Lymphoma

1 mins

UCB EHSF 2024 teaser tile image of 'medical summit'

Learning Zone

Advances in HS

30 mins

Learning Zone

All Things Angioedema and Urticaria: Podcasts

30 mins

3d rendered medically accurate illustration of a womans large intestine

Learning Zone

Ulcerative colitis Learning Zone

90 mins

Learning Zone

Psoriasis Academy

910 mins

Learning Zone

Alopecia areata Learning Zone

60 mins

Learning Zone

mCRPC in focus

1 mins

Pediatric Eosinophilic Esophagitis teaser image

Learning Zone

Type 2 Inflammation in Gastroenterology

160 mins

Myocardium Cardiac muscle fibers banner image

Learning Zone

Pompe Disease: Key findings from WMS 2022

150 mins

Doctor holding patients hand in consultation

Learning Zone

Supportive care in oncology Learning Zone

150 mins

Learning Zone

Albumin in fluid management

115 mins

Image of AI generated blood clot formation that would require pharmacological treatments available for various vascular conditions, such as anticoagulants, anti platelet agents, and vasodilators

Learning Zone

Antiplatelet therapy in ACS: Choices and Controversies

270 mins

patient receiving dialysis, hospital image

Learning Zone

Chronic Kidney Disease Learning Zone

340 mins

Webinars

Learning Zone

Recurrence in early breast cancer

40 mins

Latest news

Blue test tubes arranged in a line, disappearing into the background

Drug news

Positive results from ICONIC-Lead Phase III trial of icotrokinra (JNJ-2113) for moderate to severe plaque psoriasis

Johnson & Johnson announced positive topline results from ICONIC-LEAD, a pivotal Phase III investigational study of icotrokinra (JNJ-2113), the first targeted oral peptide that selectively blocks the IL-23 receptor, in adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO)

1 mins

Drug news

FDA approves Bimzelx (bimekizumab-bkzx) for the treatment of adults with moderate to severe hidradenitis suppurativa

UCB, announced that the FDA has approved Bimzelx (bimekizumab-bkzx) for the treatment of adults with moderate to severe hidradenitis suppurativa (HS). Bimekizumab-bkzx is the first and only approved medicine designed to selectively inhibit interleukin 17F (IL-17F) in addition to interleukin 17A (IL-17A)

1 min

Drug news

European Commisson approves Elahere (mirvetuximab soravtansine) for FRα positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer

AbbVie announced the European Commission (EC) granted marketing authorization for Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens

1 min

See all news